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Abstract
In this phase 3 trial, older patients with acute myeloid leukemia ineligible for intensive chemotherapy were randomized 2:1 to receive the 
polo-like kinase inhibitor, volasertib (V; 350 mg intravenous on days 1 and 15 in 4-wk cycles), combined with low-dose cytarabine (LDAC; 
20 mg subcutaneous, twice daily, days 1–10; n = 444), or LDAC plus placebo (P; n = 222). Primary endpoint was objective response rate 
(ORR); key secondary endpoint was overall survival (OS). Primary ORR analysis at recruitment completion included patients randomized 
≥5 months beforehand; ORR was 25.2% for V+LDAC and 16.8% for P+LDAC (n = 371; odds ratio 1.66 [95% confidence interval (CI), 
0.95–2.89]; P = 0.071). At final analysis (≥574 OS events), median OS was 5.6 months for V+LDAC and 6.5 months for P+LDAC 
(n = 666; hazard ratio 0.97 [95% CI, 0.8–1.2]; P = 0.757). The most common adverse events (AEs) were infections/infestations (grouped 
term; V+LDAC, 81.3%; P+LDAC, 63.5%) and febrile neutropenia (V+LDAC, 60.4%; P+LDAC, 29.3%). Fatal AEs occurred in 31.2% with 
V+LDAC versus 18.0% with P+LDAC, most commonly infections/infestations (V+LDAC, 17.1%; P+LDAC, 6.3%). Lack of OS benefit 
with V+LDAC versus P+LDAC may reflect increased early mortality with V+LDAC from myelosuppression and infections.
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Introduction
While acute myeloid leukemia (AML) affects people of 
all ages, the majority of patients are of advanced age, with a 
median age at diagnosis of approximately 70 years in developed 
countries.1,2 Thus, the incidence of AML is rising, at least in part, 
as a result of the aging population.2
Older AML patients are less likely than younger patients 
to achieve a complete remission (CR) with standard ther-
apy and tend to have comorbidities that prevent them 
from receiving intensive chemotherapy.3 For these patients, 
low-intensity therapies, such as subcutaneous administra-
tion of low-dose cytarabine (LDAC), are considered better 
options. As a result, LDAC has become a recommended 
therapy, and an established comparator and combination 
partner for investigational drugs, before the introduction of 
hypomethylating agents.4,5
Polo-like kinase 1 (Plk1) is a key regulator of mitosis, and its 
overexpression has been linked with poor prognosis in human 
cancer.6 Inhibition of Plk1 in vitro was found to block prolifer-
ation of leukemic cell lines, and to reduce the clonogenic poten-
tial of cell lines derived from patients with leukemia.7 Volasertib 
is a low-molecular-weight, adenosine triphosphate-competi-
tive kinase inhibitor that potently inhibits Plk1, as well as the 
2 closely related kinases, Plk2 and Plk3. In a previous study, 
volasertib treatment reduced tumor growth in colon and lung 
xenograft models, and increased apoptosis in samples derived 
from HCT 116 tumor-bearing nude mice.8 Volasertib has also 
shown robust antitumor activity in a xenograft model of AML; 
nude mice with established AML tumors treated with volasertib 
for 4 weeks experienced marked tumor regression and tolerated 
treatment well.9
In an open-label, randomized phase 2 trial, conducted in 
previously untreated AML patients aged ≥65 years who were 
ineligible for intensive therapy, objective response rates (ORRs; 
CR or CR with incomplete blood count recovery [CRi]) and 
overall survival (OS) favored volasertib in combination with 
LDAC (V+LDAC) over LDAC monotherapy (ORR: 31% versus 
13%, odds ratio [OR] 2.91, P = 0.052; median OS 8.0 versus 
5.2 months, hazard ratio [HR] 0.63 [95% confidence interval 
(CI), 0.40–1.00]; P = 0.047). There was an increase in nonhe-
matologic adverse events (AEs) with V+LDAC compared with 
LDAC; the AEs with the most pronounced increase in frequency 
included gastrointestinal AEs grade 3 (21% versus 7%), febrile 
neutropenia grade 3 (38% versus 7%), and infections grade 3 
(38% versus 7%). However, these AEs were clinically manage-
able.10 The current phase 3 study was conducted to confirm the 
results from the previous phase 2 study of the V+LDAC regi-
men for older AML patients who are unable to receive intensive 
therapies.
Materials and methods
Patients and study design
This was a prospective, randomized, double-blind, place-
bo-controlled study (NCT01721876) of V+LDAC compared 
with placebo + LDAC (P+LDAC). Eligible patients were aged 
≥65 years, had previously untreated (except for hydroxyurea) 
AML (confirmed according to World Health Organization 
criteria11), and an Eastern Cooperative Oncology Group 
Performance Status (ECOG PS) ≤2. Patients were required to 
be ineligible for intensive remission-induction therapy, based on 
documented disease and patient characteristics such as high-risk 
cytogenetics, secondary AML, and comorbidity. Exclusion cri-
teria included: prior or concomitant treatment for AML (prior 
treatment for myelodysplastic syndrome was allowed); acute 
promyelocytic leukemia; clinical signs of leukemic central ner-
vous system involvement; clinically relevant QT prolongation 
(>470 ms); and inadequate organ function (bilirubin >3× upper 
limit of normal and/or creatinine clearance <30 mL/min).
Eligible patients were randomized in a 2:1 ratio to receive 
V+LDAC or P+LDAC via an interactive voice/web response sys-
tem, stratified according to ECOG PS (0–1 versus 2) and type 
of leukemia (de novo versus secondary). LDAC was adminis-
tered subcutaneously at a dose of 20 mg twice daily on days 
1–10 of each 4-week cycle, either at the investigative site or at 
the patient’s home, and either volasertib (350 mg) or placebo 
was added as a 1-hour intravenous infusion on days 1 and 15. 
Repeated cycles of treatment (with no limit to the number) were 
administered until disease progression or relapse, according to 
protocol-defined criteria for treatment continuation and unless 
the patient or investigator requested treatment discontinuation. 
If, at the end of each treatment cycle, criteria to continue treat-
ment were not yet met, or if determined necessary by the inves-
tigator, subsequent cycles could be delayed for an unrestricted 
length of time. Dose reductions of volasertib or placebo were 
allowed in 50-mg decrements, to a minimum of 200 mg. Given 
the myelosuppressive effects of both volasertib and LDAC, 
anti-infective prophylaxis and/or growth factors such as granu-
locyte colony-stimulating factor could be administered accord-
ing to local guidelines and standards.
The trial was performed in accordance with the Declaration 
of Helsinki, the International Conference on Harmonisation 
Guideline for Good Clinical Practice, and applicable specific 
requirements, and with the approval of the respective institu-
tional review boards/independent ethics committees at each cen-
ter. All patients provided written informed consent.
Study endpoints and assessments
The primary endpoint was ORR, as determined by the central, 
blinded review of bone marrow samples and the investigator’s 
assessment (evaluation of peripheral blood and physical exam-
ination). Bone marrow examination for response assessment 
was carried out at the end of every second cycle, or as soon as 
possible if disease progression was suspected. CR and CRi were 
defined according to European Leukemia Net (ELN) recommen-
dations,5 and an additional criterion for CR was red blood cell 
transfusion independence within 7 days before response assess-
ment. The key secondary endpoint was OS, defined as the time 
interval from the date of randomization to the date of death.
Two analyses were planned according to the study protocol. 
The primary analysis was performed shortly after completion 
of patient recruitment and assessed the primary efficacy end-
point, ORR, using efficacy data from the subset of patients 
randomized ≥5 months before the cutoff date, including those 
without response data. Analysis of OS at the primary analysis 
was descriptive and exploratory. The final analysis to assess the 
key secondary endpoint, OS, included all randomized patients 
and was carried out after at least 574 OS events had occurred.
Safety was assessed by determining the incidence and inten-
sity of AEs, defined using the Common Terminology Criteria for 
Adverse Events (version 3.0), and changes in laboratory assess-
ments and electrocardiograms. Safety evaluations of the treated 
populations (all randomized patients who received at least one 
dose of trial medication) were conducted at both the primary 
and final analyses.
An independent Data Monitoring Committee periodically 
reviewed unblinded results to monitor the conduct of the trial, 
ensure patient safety, and maintain the integrity of the data.
Statistical considerations
It was estimated that approximately 371 patients should be 
included in the primary analysis of ORR, providing 90% power 
to detect an OR of 2.85 (based on the phase 2 study10 and a 
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phase 3 study of decitabine for elderly AML patients)12 using 
a 2-sided test and an alpha level of 0.05. A final planned sam-
ple size of 660 patients was selected to allow collection of an 
expected 574 OS events, assuming a dropout rate of ~10%.
The Cochran–Mantel–Haenszel test (adjusting for the 2 strat-
ification factors used for randomization) was used to compare 
ORR between treatment groups, based on a 2-sided alpha-level 
of 0.05. Mantel–Haenszel estimates for OR and 95% CI were 
calculated.
For OS, Kaplan–Meier estimates were calculated for both 
arms. A log-rank test was carried out, stratified by the same 2 
factors used for randomization. A stratified Cox proportional 
hazards model was used to estimate the HR between arms.
An unplanned, exploratory, post hoc analysis was conducted 
to better understand the difference between the phase 2 and 
phase 3 results, and to examine possible reasons for the differ-




From February 25, 2013, to November 12, 2014, 769 patients 
were screened at 122 centers in 25 countries, and 666 patients 
were subsequently randomized (V+LDAC, n = 444; P+LDAC, 
n = 222). Of these, 661 patients received the study medication 
(V+LDAC, n = 440; P+LDAC, n = 221) (Figure 1). Patient demo-
graphics and baseline disease characteristics were generally bal-
anced between treatment arms (Table 1). The most frequently 
documented medical reason for ineligibility for intensive remis-
sion-induction therapy was age (97.4%), followed by comor-
bidities (47.3%), most commonly cardiac disorders (20.7%).
Data cutoff for the primary analysis was August 12, 2014; 
371 patients had been assessed for the primary efficacy end-
point, ORR (randomized ≥5 mo before data cutoff; V+LDAC, 
n = 246; P+LDAC, n = 125), and 533 patients had been assessed 
for safety (received treatment; V+LDAC, n = 356; P+LDAC, 
n = 177). On December 18, 2014, based on the results of the 
primary analysis, blinding was suspended for all patients receiv-
ing ongoing treatment. Placebo administration was discontin-
ued and the decision whether to continue patients on unblinded 
study treatment was taken by the investigators, based on indi-
vidual benefit–risk evaluations and patient informed re-consent.
The subsequent final analysis (June 1, 2017) included all 666 
randomized patients for efficacy analyses and all 661 treated 
patients for safety analyses. The final analysis was exploratory 
and descriptive, because potential bias was introduced by the 
unblinding after the primary analysis.
At both the primary and final analyses, the mean number of 
initiated treatment cycles was higher in the P+LDAC arm ver-
sus the V+LDAC arm (3.6 versus 2.8 and 5.1 versus 4.4 cycles, 
respectively). At both analyses, the median number of treatment 
cycles initiated was 2.0 for both the P+LDAC and V+LDAC 
arms (range 1–16 and 1–14 cycles, respectively, at the primary 
analysis; and 1–38 and 1–42 cycles, respectively, at the final 
analysis), and a higher percentage of patients in the P+LDAC 
arm received >6 cycles of treatment (15.7% versus 8.2% for 
V+LDAC in the primary analysis and 22.5% versus 16.2% in 
the final analysis).
Objective response
The primary analysis failed to show a statistically significant 
benefit of V+LDAC compared with P+LDAC in the primary 
endpoint; ORR was 25.2% in patients who received V+LDAC 
versus 16.8% in patients who received P+LDAC (OR 1.66 
[95% CI, 0.95–2.89]; P = 0.071; Table 2). In the final analysis, 
the proportion of patients in the V+LDAC arm who achieved 
ORR was higher than in the P+LDAC arm (27.7% versus 
17.1%; OR 1.88 [95% CI, 1.24–2.83]; P = 0.002; Table 2).
The proportion of patients who had no response assessment 
or were not evaluable for response was higher in the V+LDAC 
arm compared with P+LDAC (38.6% versus 12.8% in the pri-
mary analysis and 35.6% versus 17.6% in the final analysis). 
The majority of these cases were due to early death prior to the 
planned first response assessment at the end of treatment cycle 2 
(Table 2). These patients were included in the primary efficacy 
analysis, although no response data were available.
Subgroup analysis of ORR showed differences in response 
rates by gender, age, weight, ECOG PS, 2010 ELN genetic risk 
group,13 type of AML, NPM1 mutation status, and geographi-
cal region of enrollment, with a trend toward better ORR with 
V+LDAC compared with P+LDAC in most subgroups (Table 3). 
Notably, in the ECOG 2 subgroup, the addition of volasertib to 
LDAC seemed to negatively impact on the outcome, whereas in 
the ECOG 0 and 1 subgroups, respectively, the response analy-
ses indicate a potential benefit with the addition of volasertib. 
Subgroup analysis of other genetic aberrations found in AML, 
such as mutations in FLT3 and CEBPA, was not conducted due 
to the small number of patients with these mutations in this 
trial.
Overall survival
In the primary analysis, numerically shorter, but not statisti-
cally significant, OS was seen for the V+LDAC arm compared 
with the P+LDAC arm (median 4.8 versus 6.5 months; HR 1.26 
[95% CI, 0.95–1.67]; P = 0.113; Figure 2). At the final anal-
ysis, survival probability over time was similar between the 2 
treatment arms, with a median OS of 5.6 months on V+LDAC 
and 6.5 months on P+LDAC (HR 0.97 [95% CI, 0.82–1.16]; 
P = 0.757; Figure 2).
Subgroup analyses of OS based on baseline factors are pro-
vided in Supplemental Table 1, Figures 1 and 2, http://links.lww.
com/HS/A177. Of note, in the respective ECOG 0 and 1 sub-
groups, the addition of volasertib to LDAC appeared to indicate 
a potential benefit. In the ECOG 2 subgroup, however, the addi-
tion of volasertib appeared to negatively impact OS.
Safety
Almost all patients experienced an on-treatment AE prior 
to final data cut-off (V+LDAC, 99.5%; P+LDAC, 97.7%; 
Supplemental Tables 2  and  3, http://links.lww.com/HS/A177). 
Across both arms, the most common AEs were infections/infes-
tations (grouped term; V+LDAC, 81.3%; P+LDAC, 63.5%) and 
febrile neutropenia (V+LDAC, 60.4%; P+LDAC, 29.3%). The 
most commonly reported AEs in the individual arms were febrile 
neutropenia, thrombocytopenia, anemia, and neutropenia in the 
V+LDAC arm, and were nausea and pyrexia in the P+LDAC 
arm. The incidence of infections and infestations, and blood 
cytopenias were numerically higher in the V+LDAC arm than in 
the P+LDAC arm; Supplemental Table 3, http://links.lww.com/
HS/A177). Patients in the V+LDAC arm had a higher incidence 
of grade ≥3 infections/infestations than patients in the P+LDAC 
arm (58.1% versus 38.3%; HR 1.77 [95% CI, 1.39–2.27]; 
P < 0.0001). Similarly, the incidence of febrile neutropenia was 
higher in patients receiving V+LDAC than in patients receiving 
P+LDAC (60.4% versus 29.3%; HR 2.84 [95% CI, 2.16–3.73]; 
P < 0.0001).
The incidence of grade ≥4 AEs was higher in the V+LDAC 
arm, compared with the P+LDAC arm. The most common 
grade 4 AEs in both arms were thrombocytopenia and neu-
tropenia, and the difference in grade 4 AE frequency between 
treatment arms was driven by increased incidences of sepsis, 
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febrile neutropenia, thrombocytopenia, anemia, neutropenia, 
and leukopenia in the V+LDAC arm. Importantly, AEs leading 
to death (grade 5) were reported with a higher frequency in 
the V+LDAC arm (31.2%) than in the P+LDAC arm (18.0%), 
potentially driven by a higher incidence of infections and infes-
tations (17.1% versus 6.3%; Supplemental Table 3 and Figure 3, 
 http://links.lww.com/HS/A177).
To further explore the difference in infectious complications 
between the treatment arms, we investigated the incidence, 
severity, and duration of neutropenia. Grades of neutrope-
nia were similar between the treatment arms at baseline, with 
the lowest (grade 4) neutrophil levels reported in 39.1% and 
46.4% of patients receiving P+LDAC and V+LDAC, respec-
tively. However, over the course of treatment, more patients in 
the V+LDAC arm than in the P+LDAC arm experienced wors-
ening of neutropenia, with grade 4 neutrophil values reported in 
94.3% of patients receiving V+LDAC compared with 75.8% of 
patients receiving P+LDAC.
AEs in the grouped term mucositis were mostly of grade 
1 or 2, but these AEs may have contributed to infectious 
complications. The frequency of any-grade mucositis (grouped 
term) was higher in patients receiving V+LDAC (33.3%) than in 
those receiving P+LDAC (12.6%). This difference in incidence 
between arms was driven by the most common AE terms in the 
grouped category, stomatitis and mucosal inflammation.
The majority of patients received treatment with antibiot-
ics or antifungals during the study, and treatment with these 
was more frequent in the V+LDAC arm (antibiotics 95.2% 
and antifungals 76.1%) than in the P+LDAC arm (antibiot-
ics 85.6% and antifungals 56.3%). The mean duration of 
antibiotic or antifungal use was similar between treatment 
arms.
Exploratory analyses
Subsequent to the primary analysis, ad hoc exploratory anal-
yses were conducted to understand the difference in outcomes 
between the previous phase 2 study10 and the current phase 3 
trial, and the possible reasons why this phase 3 trial did not 
meet its primary endpoint. One possible cause is differences in 
Figure 1. Disposition of patients included in the final analysis. AEs = adverse events; AML = acute myeloid leukemia; LDAC = low-dose cytarabine; MDS = myelodysplastic 
syndrome; RAEB = refractory anemia with excess blasts.
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cycle 1 dose intensities; protocols for the phase 2 study and this 
phase 3 trial had similar rules to allow doses to be delayed or 
skipped if required, resulting in decreased dose intensities. In 
the majority of patients in the current study, lower dose intensi-
ties were caused by a delayed start of the subsequent treatment 
cycle, that is, length of treatment cycle >28 days. In the phase 2 
trial, patients received a lower median dose intensity of vola-
sertib (17.6 mg/d) than in this phase 3 trial (20.8 mg/d). Patients 
receiving lower V+LDAC dose intensities in this phase 3 trial 
had longer OS, longer time to fatal AEs and fatal infections, and 
a higher ORR than did patients receiving V+LDAC at a higher 
dose intensity (Supplemental Figures 3–5 and Table 4, http://
links.lww.com/HS/A177).
To determine whether use of prophylactic antibiotics affected 
the incidence of fatal infections, an analysis of the time to fatal 
infection by extent of prophylactic antibiotic treatment was 
conducted. Patients in the V+LDAC arm who were not treated 
with prophylactic antibiotics had a higher risk of fatal infec-
tions than patients who received any prophylactic antibiotics 
(Supplemental Figure 6, http://links.lww.com/HS/A177).
A competing risk analysis was performed to explore sepa-
rately the effect of volasertib on OS events resulting from lack 
of efficacy or nontolerability. A benefit was observed in the 
V+LDAC arm compared with the P+LDAC arm when AML-
related deaths were considered by the investigator as potentially 
due to lack of efficacy, whilst a benefit was observed in the 
opposite direction for deaths considered by the investigator as 
potentially due to intolerability (Supplemental Figures 7 and 8, 
http://links.lww.com/HS/A177).
Discussion
The current randomized, double-blind, placebo-controlled, 
phase 3 trial was conducted to evaluate the efficacy and safety 
of volasertib, a highly potent and selective Plk inhibitor, com-
bined with LDAC in previously untreated older patients with 
AML who were considered unsuitable for intensive chemother-
apy, and aimed to confirm the encouraging results from the pre-
vious, randomized, open-label, phase 2 trial.10
The primary endpoint was not met; in the primary analy-
sis, V+LDAC was not associated with significantly higher ORR 
compared with P+LDAC. In the final analysis, the proportion 
of patients who achieved an objective response was higher in 
the V+LDAC arm than in the P+LDAC arm; however, a sub-
stantially greater number of patients receiving V+LDAC had no 
response assessment or were not evaluable, primarily because of 
a higher death rate prior to the first response assessment at the 
end of cycle 2. In the subgroup analysis, the addition of vola-
sertib to LDAC in patients in the ECOG 2 subgroup seemed to 
negatively impact the ORR.
Table 1
Baseline Patient Demographics and Disease Characteristics
Characteristic
Primary Efficacy Analysis Set Final Analysis Set
P+LDAC (n = 125) V+LDAC (n = 246) P+LDAC (n = 222) V+LDAC (n = 444)
Sex, n (%)     
 Male 75 (60.0) 140 (56.9) 135 (60.8) 241 (54.3)
 Female 50 (40.0) 106 (43.1) 87 (39.2) 203 (45.7)
Race, n (%)     
 White 88 (70.4) 181 (73.6) 158 (71.2) 328 (73.9)
 Asian 21 (16.8) 39 (15.9) 39 (17.6) 74 (16.7)
 Other/missing 16 (12.8) 26 (10.6) 25 (11.3) 42 (9.5)
Age, median (min–max) 75.0 (65–85) 75.0 (65–93) 76.0 (65–88) 75.0 (65–93)
ECOG PS, n (%)     
 0 27 (21.6) 48 (19.5) 53 (23.9) 100 (22.5)
 1 65 (52.0) 136 (55.3) 117 (52.7) 241 (54.3)
 2 33 (26.4) 62 (25.2) 52 (23.4) 103 (23.2)
WBC count/nL, n (%)     
 <10/nL 86 (68.8) 173 (70.3) 149 (67.1) 310 (69.8)
 ≥10/nL and <50/nL 36 (28.8) 52 (21.1) 62 (27.9) 104 (23.4)
 ≥50/nL 3 (2.4) 21 (8.5) 11 (5.0) 30 (6.8)
Type of AML, n (%)     
 De novo 64 (51.2) 130 (52.8) 114 (51.4) 230 (51.8)
 Secondary AML 61 (48.8) 116 (47.2) 108 (48.6) 214 (48.2)
  Preceding MDS 45 (36.0) 83 (33.7) 77 (34.7) 162 (36.5)
  Preceding MPS 8 (6.4) 17 (6.9) 18 (8.1) 28 (6.3)
  Therapy-relateda 8 (6.4) 16 (6.5) 12 (5.4) 24 (5.4)
  Other 3 (2.4) 11 (4.5) 10 (4.5) 17 (3.8)
2010 ELN genetic group, n (%)     
 Favorable 13 (10.4) 28 (11.4) 21 (9.5) 47 (10.6)
 Intermediate I 38 (30.4) 80 (32.5) 71 (32.0) 144 (32.4)
 Intermediate II 33 (26.4) 42 (17.1) 46 (20.7) 75 (16.9)
 Adverse 36 (28.8) 82 (33.3) 70 (31.5) 142 (32.0)
 Missing 5 (4.0) 14 (5.7) 14 (6.3) 36 (8.1)
Mutation types, n (%)     
 NPM1 16 (12.8) 35 (14.2) 29 (13.1) 68 (15.3)
 FLT3 ITD 6 (4.8) 13 (5.3) 8 (3.6) 22 (5.0)
aPrior therapy with alkylating agents or topoisomerase II inhibitors.
AML = acute myeloid leukemia; ECOG PS = Eastern Cooperative Oncology Group Performance Status; ELN = European LeukemiaNet; ITD = internal tandem duplication; MDS = myelodysplastic syndrome; 
MPS = myeloproliferative syndrome; P+LDAC = placebo plus low-dose cytarabine; V+LDAC = volasertib plus low-dose cytarabine; WBC = white blood cell.
6
Döhner et al Phase 3 Trial of Volasertib in Acute Myeloid Leukemia
In the primary analysis, the numerically shorter OS observed 
in the V+LDAC arm, in comparison with the P+LDAC arm, was 
likely due to a higher frequency of fatal infections in patients 
receiving V+LDAC. The study was subsequently unblinded, 
which may have influenced subsequent patient management, 
medical decision making, and, consequently, the outcomes seen 
in the trial. The final analysis, which demonstrated no difference 
in OS between treatment arms should, therefore, be considered 
exploratory and descriptive only. The competing risk modeling 
of survival endpoints indicated fewer deaths potentially due to 
lack of efficacy, but more deaths potentially due to intolerabil-
ity, in the V+LDAC arm compared with P+LDAC arm. Such 
competing risk analyses are particularly important for oncology 
studies of elderly patients, since many older patients may die 
of non-cancer-related causes rather than from a lack of treat-
ment efficacy.14 The particularly adverse OS of patients with 
ECOG PS 2 treated with V+LDAC contributed to the OS trend 
in the V+LDAC arm, most likely because frailer patients were 
at higher risk of severe AEs associated with volasertib treat-
ment. Although previous studies have reported very low rates or 
absence of remissions with LDAC for patients with an adverse 
genetic profile,4,5 in the final analysis of this study, CR or CRi 
was reported in 14.3% of patients in the adverse genetic group 
who received P+LDAC, and in 17.6% of patients who received 
V+LDAC.
More grade ≥4 AEs and almost twice as many grade 5 AEs 
were reported in the V+LDAC arm compared with the P+LDAC 
arm. This was attributed to the more pronounced myelosup-
pression observed in the V+LDAC treatment group, in addition 
to the higher reported frequency of mucositis. These results were 
expected based on the mode of action of volasertib and on pre-
vious clinical studies;15–18 volasertib was expected to transiently 
inhibit the proliferation of normal dividing cells, leading to tem-
porary myelosuppression, and increasing the risk of associated 
complications such as febrile neutropenia, infections, or throm-
bocytopenic bleeding.
The results of our exploratory analyses suggested that differ-
ences in dose intensity may have influenced outcomes. Median 
dose intensities resulted from medical assessment and deci-
sion-making by investigators; dose intensities were different 
between the previous phase 2 study and the current phase 3 
study, although both studies had similar rules to adapt dosing. 
Additionally, the open-label nature of the phase 2 study versus 
the double-blind phase 3 design might have influenced medi-
cal assessment and decision making and, thus, dose intensity. 
Patients receiving a lower dose intensity of volasertib (and 
therefore also LDAC) in this phase 3 trial had a longer time to 
fatal AEs and fatal infections, which were some of the major 
factors contributing to the poorer OS in the V+LDAC arm com-
pared to the P+LDAC arm.
Supportive care could potentially influence outcomes, 
and improvement of supportive care with the compulsory 
administration of prophylactic antibiotics/antifungals and 
blood transfusions may be advisable to proactively manage 
treatment-induced myelosuppression and avoid infections. 
Of note, the recommendations for supportive care were sim-
ilar across the phase 2 and phase 3 studies, both of which 
allowed supportive care use at the investigator’s discretion. 
The results of our exploratory analyses suggest that prophy-
lactic antibiotics may reduce the risk of fatal infections in 
patients treated with volasertib. Effective supportive care, 
along with reduction in dose intensity, may improve toler-
ability in patients receiving volasertib combination therapy, 
and ultimately improve OS.
A numerically higher ORR but no corresponding increase in 
survival for V+LDAC compared with P+LDAC is consistent with 
the results of trials testing other novel agents in older patients 
with AML who are ineligible for intensive chemotherapy. 
Table 2
Response Rates by Treatment Arm: Primary and Final Analyses
 Primary Analysis Final Analysis
 P+LDAC (n = 125) V+LDAC (n = 246) P+LDAC (n = 222) V+LDAC (n = 444)
Patients who achieved CR, n (%) 12 (9.6) 23 (9.3) 27 (12.2) 67 (15.1)
Patients who achieved CRi, n (%) 9 (7.2) 39 (15.9) 11 (5.0) 56 (12.6)
Patients who achieved CR or CRi, n (%) 21 (16.8) 62 (25.2) 38 (17.1) 123 (27.7)
 95% CIa 11.26–24.32 20.19–30.98 12.73–22.62 23.74–32.04
 OR V+LDAC vs P+LDACb 1.66 1.88
 95% CI 0.95–2.89 1.24–2.83
 P 0.071 0.002
No response assessment/not evaluable for response, n (%) 16 (12.8) 95 (38.6) 39 (17.6) 158 (35.6)
Death ≤28 d after randomization, n (%) 4 (3.2) 27 (11.0) 8 (3.6) 52 (11.7)
Death >28 and ≤56 d after randomization, n (%) 7 (5.6) 30 (12.2) 16 (7.2) 50 (11.3)
Death >56 and ≤84 d after randomization, n (%) 0 8 (3.3) 2 (0.9) 18 (4.1)
Median OS, mo (95% CI) 6.5 (5.1–8.1) 4.8 (3.8–6.4) 6.5 (4.9–8.0) 5.6 (4.5–6.8)
 HR V+LDAC vs P+LDAC 1.26 0.97
 95% CI (0.9–1.7) (0.8–1.2)
 P 0.11 0.76
Median EFS, mo (95% CI) 3.1 (2.1–5.8) 2.8 (2.3–3.8) 2.8 (2.1–4.9) 3.3 (2.6–4.2)
 HR V+LDAC vs P+LDAC 1.18 0.96
 95% CI (0.9, 1.6) (0.8, 1.2)
 P 0.26 0.67
Median RFS, mo (95% CI) NE (3.7–NE) 4.9 (3.6–13.4) 18.7 (11.3–NE) 13.1 (6.2–NE)
 HR V+LDAC vs P+LDAC 1.26 1.37
 95% CI (0.4–4.1) (0.7–2.7)
aWilson’s CI.
bOdds ratio derived from a Cochran–Mantel–Haenszel test stratified by baseline ECOG PS and type of AML. OR > 1 favors V+LDAC.
CI = confidence interval; CR = complete remission; CRi = complete remission with incomplete blood count recovery; EFS = event-free survival; HR = hazard ratio; NE = nonevaluable; OR = odds 
ratio; OS = overall survival; P+LDAC = placebo plus low-dose cytarabine; RFS = relapse-free survival; V+LDAC = volasertib plus low-dose cytarabine.
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Clofarabine showed significantly superior ORRs compared 
with LDAC, but failed to show a survival benefit because the 
increased remission rate was obtained at a cost of greater toxic-
ity.19 Addition of gemtuzumab ozogamicin to LDAC improved 
ORR but did not improve OS due to inferior survival after 
relapse. Additionally, in patients who did not achieve remission, 
survival was inferior in those who received the combination in 
comparison to those who received LDAC alone.20
As a result of the observed disparity between response rate 
and survival outcomes, there is ongoing debate as to whether the 
response rate is a good predictor of OS and whether it is suitable 
as a surrogate endpoint in trials of AML.21,22 A meta-analysis of 
20 trials in AML showed a significant correlation between rates 
of CRi or better and median OS,23 supporting the use of CR plus 
CRi as the primary endpoint in this study.
At the time this study was designed, LDAC was considered 
the standard treatment for patients with AML who were inel-
igible for standard intensive chemotherapy. Since then, the 
hypomethylating agents azacitidine and decitabine have been 
introduced into therapy guidelines as recommended treatment 
for these patients.5 These agents may now be considered the 
preferred combination partners and comparators for clinical 
trials. Furthermore, in the phase 1b/2 M14-358 and phase 1b 
M14-387 studies, the BCL-2 inhibitor, venetoclax, in combi-
nation with azacitidine, decitabine, or LDAC, demonstrated 
encouraging CR rates and remission duration in AML patients 
of older age (≥60 yrs) or with comorbidities precluding the 
use of intensive induction chemotherapy. The pivotal phase 3 
VIALE-A trial reported that, in patients with AML who 
were ineligible for intensive induction therapy due to comor-
bidities or age, treatment with venetoclax and azacitidine 
led to a significant improvement in OS (14.7 versus 9.6 mo, 
P < 0.001), composite complete remission (CR + CRi; 66.4% 
versus 28.3%, P < 0.001) and event-free survival (9.8 versus 
7.0 months, P < 0.001), compared to treatment with pla-
cebo and azacytidine.24 Venetoclax in combination with a 
hypomethylating agent or LDAC therefore offer new therapy 
options for these patients.25–27
This randomized phase 3 trial did not meet its primary end-
point of ORR in the primary analysis, and did not confirm the 
survival benefits of volasertib in combination with LDAC seen 
in a previous randomized phase 2 study.10 There was a notably 
higher rate of fatal infections in patients who received V+LDAC, 
indicating that the volasertib dose and schedule used were not 
sufficiently tolerable. Development of volasertib was discon-
tinued in 2018, following a strategic decision by the sponsor. 
Nevertheless, the results of this trial provide insight into the effi-
cacy and tolerability of volasertib in older patients with AML, 
and may inform development of other Plk1 inhibitors.
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